Menu Search
Equities

Hansoh Pharmaceutical Group Company Ltd

3692:HKG.HZ

Hansoh Pharmaceutical Group Company Ltd

Actions
  • Price (HKD)17.12
  • Today's Change-0.26 / -1.50%
  • Shares traded5.45m
  • 1 Year change+20.22%
  • Beta--
Data delayed at least 15 minutes, as of Nov 13 2024 08:08 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Hansoh Pharmaceutical Group Company Ltd is an investment holding company primarily engaged in the research and development, production and sale of a series of pharmaceutical products. The Company’s innovative drug products include Ameile, Hansoh Xinfu, Mailingda, Fulaimei, Hengmu, XINYUE, Saint Luolai and other products. The Company’s drug products are mainly used in oncology, anti-infective diseases, central nervous system (CNS) diseases, metabolic diseases and other therapeutic areas. The Company mainly conducts its business in the domestic market.

  • Revenue in HKD (TTM)13.04bn
  • Net income in HKD5.08bn
  • Incorporated2015
  • Employees9.10k
  • Location
    Hansoh Pharmaceutical Group Company Ltd287 Xiangke Road, Pudong New DistrictSHANGHAI 201210ChinaCHN
  • Websitehttp://www.hspharm.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.